<i>Saccharomyces cerevisiae </i>I-3856 in irritable bowel syndrome with predominant constipation
Florian Mourey, Amélie Cayzeele Decherf, Jean-François Jeanne, Mathieu Clément‐Ziza, Marie-Lise Grisoni, François Machuron, Sophie Legrain–Raspaud, Arnaud Bourreille, Pierre Desreumaux
Abstract
BACKGROUND: ) I-3856 has already demonstrated beneficial effects in IBS subjects, particularly in IBS with predominant constipation (IBS-C). AIM: I-3856 in the management of gastrointestinal symptoms in IBS-C. METHODS: CFU daily) or the placebo for 8 wk, and they performed daily self-evaluations of gastrointestinal symptoms. The primary objective was to assess the effect of the probiotic on abdominal pain. The secondary objectives were the evaluation of other gastrointestinal symptoms, bowel movement frequency and consistency, and quality of life (QOL). RESULTS: nonresponders. CONCLUSION: I-3856 in IBS-C. Abdominal pain relief was associated with improved QOL. ClinicalTrials.gov identifier: NCT03150212.